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Abstract Multicomponent, synergistic and multifunctional nanostructures have taken over the
spotlight in the realm of biomedical nanotechnologies. The most prospective materials for bone
regeneration today are almost exclusively composites comprising two or more components that
compensate for the shortcomings of each one of them alone. This is quite natural in view of the
fact that all hard tissues in the human body, except perhaps the tooth enamel, are composite
nanostructures. This review article highlights some of the most prospective breakthroughs made
in this research direction, with the hard tissues in main focus being those comprising bone, tooth
cementum, dentin and enamel. The major obstacles to creating collagen/apatite composites
modeled after the structure of bone are mentioned, including the immunogenicity of xenogeneic
collagen and continuously failing attempts to replicate the biomineralization process in vitro.
Composites comprising a polymeric component and calcium phosphate are discussed in light of
their ability to emulate the soft/hard composite structure of bone. Hard tissue engineering
composites created using hard material components other than calcium phosphates, including
silica, metals and several types of nanotubes, are also discoursed on, alongside additional
components deliverable using these materials, such as cells, growth factors, peptides, antibiotics,
antiresorptive and anabolic agents, pharmacokinetic conjugates and various cell-specific
targeting moieties. It is concluded that a variety of hard tissue structures in the body necessitates
a similar variety of biomaterials for their regeneration. The ongoing development of
nanocomposites for bone restoration will result in smart, theranostic materials, capable of acting
therapeutically in direct feedback with the outcome of in situ disease monitoring at the cellular
and subcellular scales. Progress in this research direction is expected to take us to the next
generation of biomaterials, designed with the purpose of fulfilling Daedalus’ dream - not
restoring the tissues, but rather augmenting them.
Keywords: Apatite; Bone; Calcium phosphate; Nanoparticle, Scaffold, Tissue engineering.
Highlights: 1) Most prospective breakthroughs made in composites for bone engineering. 2)
Smart materials acting therapeutically in feedback with in situ disease monitoring. 3) Bone as an
example of a composite where strengths compensate for weaknesses. 4) Ceramic/polymer
composites modeled after the structure of bone. 5) Future generation of biomaterials that restore,
but also augment repaired tissues.

1. Introduction
Because of the continuously aging human population on Earth and the corresponding rise
in the incidence of hard tissue diseases 1, increasing incentives exist to develop methods for
minimally invasive regeneration of dysfunctional mineralized tissues. Complications faced by
bioengineers in attempts to recreate and regenerate impaired hard tissues are, however, numerous
and they appear logical in view of the fact that hard tissues are Nature’s most intricate materials
in the classical sense of the word. Their variety within the human body itself is relatively large
and the example demonstrating the extraordinary complexity of even arguably the simplest one
of them, the tooth enamel, is presented in Fig.1. The microstructure of enamel, the strongest, but
also the most brittle hard tissue in the human body 2, is dominated by rod-shaped bundles of
apatite fibers whose aspect ratio reaches up to 3 · 104 and which are arranged perfectly parallel to
each other. Enamel is also 96 - 98 wt% mineral in composition, while water, lipids and various
peptides, generally treated as impurities with no functional role at all, account for the rest 2 – 4
wt%. In contrast to enamel, dentin and bone are both collagenous composites and it is usually
presumed that there is little or no difference between them at the nanometer scale 3. A substantial
difference, however, exists at the micro scale. Namely, while bone is composed of parallel arrays
of osteons, each one of which is a laminated cylindrical structure, ~ 200 µm in diameter, wherein
individual lamellae contain uniaxially oriented collagen fibers mineralized by nanoscopic apatite
platelets, dentin is composed of tubules with hypermineralized edges and ~ 1 - 2 µm in diameter
interspersed inside of the intertubular matrix whose composition at the submicron scale is
identical to that of bone (Fig.2). One finds here type I collagen fibrils reinforced by the
nanosized intrafibrillar and extrafibrillar plate-shaped apatite crystals 4. Tooth cementum, the
fourth and the final apatitic hard tissue in the human body, is another collagenous composite with
apatite as the mineral phase 5, containing also considerable amounts of proteoglycans and a minor
proportion of glycoproteins 6.

Fig.1. Histological section of the developing human tooth in the maturation stage (left) and a micrograph showing
parallel arrangement of enamel rods (right). 1 – ameloblasts; 2 - enamel; 3 – dentin; 4 – odontoblasts; 5 – pulp. Each
enamel rod is composed of a myriad of thin apatite fibers, each with approximately 40 – 60 nm in diameter.

Fig.2. (a) Scanning electron micrograph of a slice of dentin showing tubules, peritubular mineral (white arrow) and
the collagenous intertubular matrix (black arrow); (b) Collagen fibrils interconnected by noncollagenous proteins
and extrafibrillar mineral; (c) Collagen molecules display a typical spacing of 67 nm. Gap region equals 40 nm and
the overlap region is 27 nm in length, which together gives the typical periodicity of 67 nm; (d) Intrafibrillar mineral
particles are shown positioned in the gap region between collagen molecules. Reprinted with permission from Ref.7.

All hard tissues in the human body are composites. Even the tooth enamel, whose organic
ingredients used to be treated as impurities, is nowadays increasingly classified as a composite
structure 8. An argument given in support of this is that even the entrapment of a two orders of
magnitude lower concentration of macromolecules than that present in enamel would markedly
increase its strength 9. This particularly applies to its toughness, as a hypothetic enamel made of
apatite only is expected to be far more brittle along specific crystallographic directions than
natural enamel. A biological material referable to for the sake of supporting this argument is the
spine of sea urchin, which contains only 0.02 wt% of glycoproteins (~ 1 protein molecule per
each 105 unit cells). Although this amount is significantly lesser than the 3 wt% of organics in
nacre 10, it appears to be large enough to efficiently absorb the energy from propagating cracks
and thus markedly enhance the resistance of the material to fracture 11.
All hard tissues in the human body are also nanostructures. For a material to receive the
attribute of a “nanostructure” in the domain of chemical engineering, it has to be composed of
particulate units whose at least one spatial dimension does not exceed 100 nm. Biomedical
engineering has modified this definition over the years by pushing this critical size limit up to 1
μm. Therefore, what regularly classifies as a nanostructure in the medical literature need not be a
nanomaterial according to the convention established by materials scientists. As per the standard
definition, even though the length of the apatite fibers in enamel reaches between 100 μm and 1
mm, their diameter is in the range of 40 – 60 nm, which classifies enamel as a nanostructure. The
same can be said for dentin and bone, both of which are composed of apatite crystals with the
average dimensions of 30 x 20 x 2 nm 12. Nanocomposites, the subjects of this review, are by
definition “multiphase solid materials where one of the phases has one, two or three dimensions
of less than 100 nanometers” 13. Accordingly, even a material whose bulk is composed of
micrograins but whose thin film coating is nanoparticulate in nature classifies as a
nanocomposite. More than one of such materials will be elaborated in this review.

Due to the aforementioned versatility of hard tissue structures in the body, including that
within bone itself (cancellous, a.k.a. trabecular or spongy bone, comprising 20 % of bone weight,
is, for example, far more porous and vascular than cortical bone, having approximately ten times
higher specific surface area than the latter), different methods and materials are required to
regenerate the impaired hard tissues of different type. To that end, no perfect material exists, as
every one of them suffers from specific weaknesses. Rule of thumb, excluding the exceptions,
says that metals have superior mechanical properties, but the elastic modulus mismatch can lead
to adjacent bone resorption and inferior biomechanical integration, let alone that ultra-corrosive
magnesium alloys are the only biodegradable metals that could be used in sustained drug
delivery. Ceramics have excellent bioactivity, good tissue integration properties and easily
controllable bioresorption profiles, but low tensile strength and unsatisfactory toughness cause
problems for load-bearing applications. Polymers are perhaps more versatile than any other type
of materials in bone engineering, the reason for which they are more applied as biomaterials than
any other material type 14, having high flexibility and resistance to failure due to fatigue, but the
necessity of sacrificing strength on the account of biodegradability disfavors their sole use as
bone substitutes.
Another general bioengineering principle is that a single biomaterial cannot prove to be
ideal for two different applications in the body 15. Materials successfully applied for the repair of
cartilage have been, for example, notoriously inefficient in healing the subchondral bone and
vice versa, which has led to the drawing of a firm line between materials for chondral
regeneration and the materials for osteochondral regeneration. Drug delivery materials that
release drugs at a moderate and sustained rate, with zero-order kinetics, may work well for
osteoporotic patients, but may not be applicable in the treatment of osteomyelitis, where a burst
release and a higher order kinetics proves to be more desirable 16. Relatively small particles (~ 50
nm) tend to have a higher cell uptake efficiency and a greater potential for gene therapy than
their larger counterparts, but the cost alongside a lesser retention time 17 is their less efficient
contravention of the vascular flow and a lower level of control using external fields 18, which is
why differently sized therapeutic particles may prove to suit the cell-targeting treatment of the
less vascular cortical bone and the more vascular trabecular bone. Then, bone is populated by
biomolecules and cells specialized for different, often mutually antagonistic roles: bonedepositing osteoblasts and bone-resorbing osteoclasts, nucleation-promoting osteocalcin and
nucleation-hindering osteopontin, bone morphogenetic protein-7 and transforming growth factorβ2 19, proteoglycans and matrix metalloproteases are only some of the examples. For this reason,
diametrically opposite stimuli provided by single scaffolds may prove to be necessary to
maximize the osteogenic response to an implant, something that could be achieved only using
complex composite materials. Nevertheless, with all hard tissues in the body being composite
nanostructures, it is expected that an ideal biomaterial applicable in regeneration or substitution
of the given tissues should be a composite nanostructure too. The following discourse will
highlight some of the most prospective breakthroughs made in this research direction, with the
hard tissues in main focus being those comprising bone.
2. Collagen/apatite composites modeled after the structure of bone
The future of all fields of engineering at the nano scale, including bioengineering, can be
said to belong to composite, synergetic, multifunctional materials 20. As an illustration, Fig.3
correspondingly displays the dramatic annual increase in the number of publications deposited at

the US National Library of Medicine for which keywords are “bone engineering” and
“composite”, from only 1 in 1980 to 4 in 1990 to 21 in 2000 to 158 in year 2010 to 260 in year
2014, more than in any year before. Single-phase nanomaterials have been explored relatively
well in the past, perhaps with the exception of supramolecular constructs and stoichiometrically
complex ceramics 21. Consequently, as of a few years ago, multi-component nanostructures have
taken over the spotlight in the realm of nanotechnologies. Bone is an example of one such
material, as the strengths of both of its components compensate for the inevitable weaknesses of
each: i.e., apatite crystals, strong to compression, but weak under tension and also brittle, not
tough, impart high elastic modulus to the bone, while collagen yields toughness and high tensile
strength to it 22. The result of this combination is such that the resilience of bone is much greater
than the mere sum of the mechanical properties of its basic components; hence, we are free to
say that, figuratively, 1 + 1 > 2. As is the case with the tooth enamel, the exceptional stiffness
and strength of bone come not only from the synergistic combination of material properties of its
mineral and organic components, but from its hierarchical, multi-scale organization as well. In
fact, so versatile is the hierarchical organization of bone that it has been proposed that the bone
be treated not as a single material, but as a whole family of them 23. With the exception of cariesaffected hard tissues, which come to contain detectable levels of brushite 24, apatite, a
nonstoichiometric form of hydroxyapatite (HAp) in which approximately one-fifth of Ca2+ ions
are substituted with cationic impurities while carbonate ions contribute to 2 - 8 % of its weight, is
the only other mineral component of hard tissues in the human body.

Fig.3. Annual number of publications deposited at the US National Library of Medicine for the period 1976 – 2014
and matching the keywords “bone engineering” and “composite”.

With bone being composed of mainly collagen and apatite, the most logical approach to
fabrication of materials for bone replacement may seem to be the structural replication of bone
itself 25,26. Two main problems are, however, associated with this approach. First, to faithfully
replicate a complex composite structure that bone is, entwinement of the intrinsic components at
the micro scale is not enough 27. What is needed is the replication of their exact interaction at the
finest, molecular scale. Only after this is accomplished can more complex bony structures be
expected to be built. For, although there is a great variety in the superstructural ordering of
mineralized collagen fibers depending on the bone type and species, they are all hypothesized to

have been created from the building blocks and interactions that are identical at the molecular
scale 28. As shown in Fig.2, depending on which one of the two possible sites in the collagen
matrix apatite crystals occupy, they could be either intrafibrillar or extrafibrillar, the former of
which are particularly important in stabilizing the bone structure, as they fit in the discreet gap
between overlapping collagen fibrils and are in no way randomly distributed throughout the
protein matrix, as is the case with the extrafibrillar mineral. The filling of intrafibrillar spaces
with the mineral particles typically leads to their lesser prominence during high-resolution
imaging, and vice versa. There are also indications that, contrary to earlier assumptions,
mineralization of collagen fibrils proceeds by filling the overlap region first and the gap region
afterwards 29. This suggests that the mineralization of the organic matrix of bone is a process far
more intricate than it may seem at first and that an unselective deposition of apatite throughout
the collagenous matrix cannot be a successful means to replicate the structure of bone at the
molecular scale, which is, on the other hand, the basis of the stability of all the higher levels of
its superstructural order. In vitro remineralization of dentin has consequently produced markedly
weaker materials in cases when the newly deposited mineral was not chemically connected to the
already present intrafibrillar apatite particles 30.
The c-axis of apatite crystals in bone, [001], is known to be oriented parallel to the long
axis of the collagen fibrils 31. Examples from catalysis have demonstrated that the exposition of
different surface faces can yield a drastically different reactivity of the catalyst, and the precise
crystallographic orientation of apatite crystals in bone is probably a crucial factor in determining
its unique mechanical properties. The boundary between the 40 nm wide gap and the 27 nm wide
overlap zone in collagen fibrils is where the onset of the mineralization is presumed to occur and
Ca2+ ions furthermore tend to be positioned in the valleys between the positively charged peaks
of collagen molecules. It is possible that if this exact formation mechanism is not perfectly
replicated at the molecular scale, the structural failure of the resulting composite will ensue. Due
to the complexity of this process, no attempts to reproduce the fine composite structure of bone
by artificial means have been successful so far. A corollary of this fact is that no bone substitute
for load-bearing applications is available to the orthopedic clinicians, as of today 32.

Fig.4. A scheme illustrating the mineralization of collagen fibrils. Reprinted with permission from Ref.33.

Fig.4 offers a schematic description of stages in the amorphous-cluster-mediated process
of incorporation of apatite crystallites into the network of collagen fibrils. Although no

agreement could have been reached for more than a decade regarding whether individual ions or
amorphous clusters present the growth units during biomineralization events in general, an
informal consensus has been reached in the recent years that the latter mechanism more faithfully
describes this complex morphogenetic process 34. Accordingly, constitutive ions from the
extracellular matrix coalesce and form unstable units, so-called Posner’s clusters, with an
approximate Ca9(PO4)6 stoichiometry35 and 9 Å in size on average (stage 1). As a result of the
inward pull experienced by the atoms attempting to compensate the undersaturated bonds, these
anhydrous clusters are more compact than their crystalline counterparts, as measured by shorter
Ca-O bond lengths 36. The formation of these ionic clusters as precursors for the amorphous
intermediates begins in the solution even under undersaturated conditions 37. In vitro studies have
demonstrated the tendency of these clusters to be attracted to acidic amino acid residues of
proteins, in contact with which they start to aggregate, forming amorphous particles with sizes in
the order of tens of nanometers 38. Thus, having been nucleated in the extracellular matrix, the
clusters then approach the organic surface and begin to aggregate near and on it (stage 2).
Further aggregation causes densification of the growth units near the surface (stage 3) and is
followed by reorganization of the clusters first into amorphous (stage 4) and then into crystalline
particles (stage 5), which continue to grow via attachment of clusters or amorphous units. They,
however, continuously dissolve and recrystallize, all until a specific crystallographic orientation
with respect to the collagen fibrils is reached 39. According to an alternative explanation proposed
for calcite, amorphous particles form in the solution before they reach the water/organic
interface 40, with or without the help of extracellular vesicles 41. In spite of the nucleation of these
metastable clusters in the solution, they are still expected to form predominantly via
heterogeneous nucleation under low supersaturation conditions that are present in biological
milieus, given that even in the purest solutions nucleation occurs mainly on container walls, dust
particles and other impurities, including ions formed by the background cosmic radiation 42.
Phosphorylated glycoproteins, such as osteocalcin, or proteoglycans with the affinity for Ca2+
ions can act as such feasible heterogeneous nucleation surfaces for the formation of amorphous
clusters of apatite, which may subsequently detach, aggregate and become incorporated into the
collagen network.

Fig.5. Two basic types of crystal growth: diffusional (“classical”) and aggregative (“alternative”) (left) and in situ
TEM imaging of the growth of a CaCO3 crystal via aggregation of amorphous nanoparticulate precursors (right).
Reprinted with permissions from Refs. 43 and 44.

This model is in concert with the new model of crystal growth applicable presumably to
all biomineralization processes and to a large body of synthetic crystal growths too, involving
aggregation of amorphous, nano- or subnano-particulate units and their subsequent consolidation
and faceting (Fig.5). Broad acceptance of this model, less intuitive than its predecessor, the
diffusional one proponed most notably by La Mer et al. 45,46, it is important to note, took a painful

paradigm shift over two to three decades, perfectly exemplifiable by Kuhn’s classical model of
paradigm shifts in science 47. Namely, for a long time pioneers who proposed that monodisperse
particles most frequently grow by aggregation of separately nucleated subunits 48,49 were not
given the credit they deserved, especially in the absence of in situ imaging methods. In the last
decade, however, the paradigm shift has gradually occurred and now the new paradigm states
that most particles form by (a) the growth of primary, usually amorphous units by diffusion, and
(b) aggregation and rearrangement of these primary units into more crystalline and bigger
particles. Depending on the experimental conditions, the classical, La Mer’s mechanism and the
aggregative one are entwined to different extents and dominant at different stages of the
process 50. Note also that the model involving the aggregation of amorphous precursors is
entropically the most favorable pathway since the transient amorphous phase is more similar in
structure to the liquid phase from which it is precipitated than to more crystalline particles that
present the final product of the reaction.
That phase transitions should occur by the gradual transformation of the entropically
closest phases from one to another is expected from the principle postulated by D’Arcy
Thompson 51 and reiterated by the Ostwald-Lussac rule 52. While the ionic clusters in equilibrium
with the solution form on the scale of seconds under the right conditions, the subsequent
transformation from nanospherical amorphous calcium phosphate (CAP) units to somewhat
uniaxially grown Ca2+-deficient octacalcium phosphate (OCP) to stoichiometric OCP to HAp
takes place over the next 3 h or so 53. The kinetics of this process, however, greatly depends on
(a) thermodynamic factors, including supersaturation of the medium and temperature, and (b)
kinetic factors, such as the presence of a foreign surface and its properties, including chemistry,
charge and texture. During abrupt precipitation at ultrahigh supersaturations, the transient phases
are presumed to be so short-lived that they are virtually undetectable. Collapse of the inherently
unstable ionic clusters into amorphous CAP nanospheres is detectable as a drop in pH, while
Ca/P ratio grows continuously throughout the process, from ~ 0.3 for the initial clusters to 1 –
1.5 for the amorphous particles to 1.67 for HAp. For this reason, the ideal biomimetic growth of
apatite under low supersaturations, when the process is mainly surface-controlled, should start
from a solution that possesses high initial concentrations of phosphates and low initial
concentrations of Ca2+ ions 54. To verify this, an AFM study arrived at conclusion that the surface
step propagation velocity as a measure of the crystal growth rate of HAp is inversely
proportional to Ca/P ratio in the solution 55.
The second problem associated with the application of collagen as a component of bone
fillers comes from its intrinsic immunogenicity 56, a direct consequence of the fact that it is
difficult to obtain directly from the patient and that most of it is xenogeneic in nature, while
recombinant technologies as well as the methods to extract the immunogenic, telopeptide portion
of collagen molecules are not only of limited availability, but also lead to reduced bioactivity of
the protein 57. The products of its degradation in vivo, the rate of which is often very variable,
depending on the concentration of immunologically activated collagenases in the extracellular
matrix surrounding the implant, have frequently been observed to lead to fibrous capsule
formation 58. Although collagen has been successfully applied topically, e.g., as a wound dressing
carrier of antibiotics 59,60,61, its mere subcutaneous epithelialization may lead to undesired
immunogenic or antigenic responses 62. It is also difficult to shape and process for bone graft
applications, alongside being mechanically and thermally unstable. Thus, in spite of its superior
cell attachment properties and the ability to mimic the extracellular matrix by directing

migration, growth, differentiation and organization of cells, it does not present an ideal choice
for bone replacement materials.
Neither have bioderived alternatives to collagen proven more adequate for use in bone
engineering implants. For example, elastin, another insoluble extracellular matrix protein,
adopting a covalently cross-linked random coil conformation, being a key to its rubbery
meshwork elasticity, is difficult to obtain free of globular protein contamination, while it has also
caused severe calcifications in vivo owing to its excessive propensity to promote
mineralization 63. Silk fibers produced by Bombyx mori, having five times higher tensile strength
(650 MPa) and Young’s modulus (15 GPa) than collagen, are another natural compound
considered for bone filling applications 64. Silk coatings on biphasic CAP scaffolds, for example,
significantly improved their elasticity and toughness, though still far from the range of trabecular
bone 65. Silk fibers are predominantly composed of two proteins: 75 wt% β-sheet-rich and thus
water-insoluble fibroin on the inside and 25 wt% water-soluble sericin on the outside. However,
the same problem of immunogenicity evident for xenogeneic collagen has been reported to entail
the topical application of sericin on wound sites 66. The reason is that silk comes with a large
concentration of impurities - 1.5 % being carbohydrates, 0.8 % waxes, 0.7 % inorganic salts and
0.2 % pigments. Spider silk, which is even stronger to tension than that spun by Bombyx mori,
having nominal fracture strength of up to 1.1 GPa, suffers from another weakness; namely,
unlike Bombyx mori, spiders cannot be directed by domestication to produce large amounts of
silk because of their aggressive territoriality 67 and attempts to use recombinant techniques in
transgenic silkworm, bacteria, yeast and other organisms have been only partially successful 68.
Chitosan, the water-soluble derivative of chitin, yet another polymer of natural origins and the
second most abundant organic material next to cellulose, easily extractable from fungal cell walls
and crustacean shells, the byproducts of food industry 69, suffers from similar demerits, as
expensive purification methods that eliminate impurities that may cause adverse biological
reactions both in vitro and in vivo need to be implemented to ensure its safe clinical application.
Unlike polyesters, poly(ethylene glycol), gold or silica, chitosan, like poly(L-lysine), is also
positively charged, which contributes to its higher reactivity in contact with the oppositely
charged cell membrane 70,71,72 and the ability to disrupt the epithelial tight junction73,74.
Illustrative of the great mechanical potentials of chitosan composites is the fact that the one
biological material with the tensile strength higher than that of spider silk, in the range of 3 – 6.5
GPa, are limpet teeth wherein chitin matrix is reinforced by goethite nanofibers 75.
This is all to say that biomimetics stands for a very practical idea, although sometimes it
is wise to think ahead of Nature and conceive of structures that would be inspired by it and at the
same time transcend it. This is in line with the evidence coming from cognitive sciences,
showing that no evolution could be made possible if imitation out of empathy and respect were
not combined with strivings for originality and uniqueness 76. All of this might allure us to think
that artificial materials must be more prospective hard tissue engineering options than the natural
ones. Still, it would be a mistake to fall prey to the “single compound phobia” 77 proponed by the
NIH and disvalue the immense potential of natural materials, which in the short run might have
even outweighed that of their synthetic counterparts had it not been for the general dislike of the
natural medicines approach amongst the synthetically biased biomaterials community. In fact,
natural composites comprise a special subset of biomaterials that has been used as bone grafts
with success. For example, formation of a silica network in waste obtained from the production
of beer, a.k.a. bagasse, yielded a beer-born bone graft usable for a variety of orthopedic
treatments 78, whereas processed skeleton of marine algae harvested off the coast of South Africa

has been used in the clinic as an implant for maxillary sinus floor augmentation and other bone
grafting procedures 79,80. Moreover, the therapeutic potency of natural materials, many of which
could serve as excellent models to replicate in the lab using an array of different biomimetic
strategies, has not been tapped into fully yet and countless phycogenic biomaterials could still be
made and proven superior over their synthetic analogs, let alone auto-, allo- and xeno-grafts,
which still present gold standards for bone replacement materials. Biomaterials obtained from
natural sources are typified by an extremely long list of ingredients, most of which are present as
trace elements (< 0.01 wt%), acting in synergistic ways that cannot be replicated yet in their
synthetic counterparts. However, this versatility of components, mimicking that present in
biological systems with which they are meant to interface, presents both their strongest
advantage and disadvantage. For, while microelements could foster bone growth by mechanisms
not fully elucidated yet, they could also provoke an immune response in the host and lead to
severe inflammation and implant failure. Still, despite the problems entailed by the low level of
control of their chemical content and biological response, theirs is still a path worth following.
3. Polymeric/CAP composites
As is the case with pure collagen matrix, biodegradable polymers are broken down by
hydrolysis into resorbable or excretable segments, but lack the mechanical properties required
for load-bearing applications. Their combination with sturdier components is thus necessary to
make their application in the clinical repair of most hard tissues feasible. Ideally, the polymeric
matrix of higher plasticity and toughness is to inhibit the propagation of dislocations and cracks
originating in the core ceramic grains, fibers or layers of higher hardness and brittleness.
Following this R&D route, we may come closer to the ideal of a biomaterial that is both
biodegradable and mechanically strong to replace bone. Polymer/CAP composites present one
class of artificial composite materials that has attracted a particular attention of bone engineers
owing to their wide range of unique properties, particularly in terms of their ability to emulate
the soft/hard composite structure of bone. The combination of viscoelastic properties of the
polymers and osteoconductivity of CAPs has yielded materials that surpassed the resistance to
fracture, structural integrity and stiffness of the individual components 81, making up for the low
compressive strength of the former and brittleness and the lack of malleability of the latter 82.
With ceramics being generally frail when loaded in tension or shear modes, the preferred form of
application of ceramics is particulate, as opposed to fibrous or laminar. Inorganic nanoparticles
incorporated to a polymeric network have thus been shown to improve an array of properties of
the pure polymer, including stiffness, resistance to wear and crack propagation, compressive
load-bearing capacity, overall stability and even tensile strength 83. Studies have shown that
osteoblasts proliferate better on surfaces stiffer than most polymers 84 as well as that
mesenchymal stem cells (MSCs) differentiate into neurons on soft surfaces and osteoblasts on
the stiff ones 85, which explains how come the dispersion of CAP particles throughout a
polymeric matrix leads to an increased Young’s modulus and increased bioactivity of the
composite material at the same time 86. Moreover, it is a rule of thumb that biomaterials in
general should be rough so as to promote cell attachment 87,88, except in a few cases, including
joint and some soft tissue implants for which smooth surfaces are more desirable; impregnation
of polymers with inorganic nanoparticles contributes to this surface roughness and makes
additional processing steps such as etching or sandblasting unnecessary. Precipitation of HAp
throughout an acellular dermal matrix at low supersaturation, the process which is also known as

biomimetic mineralization of scaffolds, has correspondingly yielded a markedly more viable
surface for the proliferation of periodontal ligament stem cells 89. Moreover, less spindle-like and
more osteoblastic, polygonal morphological appearance of the cells was in favor of their greater
affinity to the surface when the latter contained the ceramic particles dispersed in the matrix,
while significant upregulation of two osteogenic markers - the transcription factor Runx2 and
osteopontin - was detected on HAp-containing scaffolds compared to HAp-free ones after seven
days of incubation. Complementing a ceramic powder with a viscous polymeric phase also
allows for the direct injection of the former to the bony defect, bypassing the need for surgical
implantation in certain clinical circumstances. In some cases, as when self-setting CAP cements
are used in addition to a polymer in the glassy state (e.g., PLLA or PLGA at the physiological
temperature) as an additional component, the roles may be reversed, with the ceramic phase
being viscous and contributing to the injectable character of the composite. Moreover, the
hydrolysis of polyesters exposes carboxylic acid moieties to the local biological environment 90
and their potentially unfavorable effect on it could be compensated for by delivering them with
the simultaneously degrading alkaline HAp 91.
Unlike many other polymeric composites wherein the polymeric phase is the only one
that allows for the tuning of structure, properties and performance in the synthesis stage, in the
case of polymer/CAP composites it is both phases that could have an array of properties tuned
depending on the preparation conditions. Thus, the mechanical and degradation properties of a
polymer could be modified by controlling parameters such as cross-linking degree, porosity, the
ratio and the arrangement of different monomeric units in copolymers, chain defects, the amount
of adsorbed water in hydrogels and the distributions of molecular weight, hydrophobicity and
crystallinity, while solubility of CAPs could be similarly tuned by controlling parameters such as
phase composition, crystallinity, particle size, stoichiometry, concentration of impurities, lattice
strain, etc. Polymers are by default partly crystalline and partly amorphous; the more crystalline
the polymer, the higher its brittleness and the lower its degradability tend to be. Highly
crystalline polymers do not only have more bonds to hydrolyze compared to their amorphous
counterparts, but they also limit the ingress of water to a greater extent, an effect that directly
hinders their degradation and lowers the drug release rate in cases when the polymeric particles
encapsulate or entrap a drug. Poly(α-hydroxy esters) are a family of biodegradable polymers
studied for bone and tooth engineering applications perhaps more than any other synthetic
polymer and approved for human use by the US Food and Drug Administration (FDA). The most
widely used among them are poly(L-lactic acid) (PLLA), poly(glycolid acid) (PGA), and their
combination, poly(lactic-co-glycolic acid) (PLGA). While PLLA has a relatively lengthy
degradation time scale, ranging between 10 months and 4 years 92 depending on the degree of
crystallinity, an increase in the PGA content shortens it down to a couple of months only for
PLGA 50:50, before the degradation time begins to soar again at weight ratios approaching that
of pure PGA 93,94, for which it equals anywhere between 6 and 12 months. Polyurethanes,
likewise, offer an easy control over the elasticity and the degradation rate through the carbonateto-ester bond ratio 95 and through the ratio between the aromatic and non-biodegradable, socalled “hard” segments and the aliphatic and biodegradable, so-called “soft” ones. In the case of
CAPs, one could control their aqueous solubility within a wide range, spanning from ultrahigh to
sparse, using the following phase composition sequence: monocalcium phosphates (MCP) >
dicalcium phosphates > calcium pyrophosphate > tricalcium phosphates (TCP) > amorphous
CAP > OCP > HAp 96. The solubility of different CAP phases is in most cases directly
proportional to their degradation rate following implantation. For example, the implantation of a

biphasic ceramic composed of HAp and β-TCP into rabbit tibias resulted in the resorption of
only about 5 % of HAp and 85 % of β-TCP after three months 97. Multiple authors, therefore,
consider phase mixtures of various CAPs as ideal bone grafts, including the most commonly
applied material of such type, biphasic CAP composed of sparsely soluble HAp and moderately
soluble TCP in different proportions. In some cases, however, more soluble CAP phases can be
expected to undergo surface reprecipitation of a less soluble phase, which would protect the
soluble bulk from contact with water and prolong the period of stability of the material in the
body. Alongside its propensity to hinder the implant replacement with the newly ingrown bone,
this effect is also particularly critical for drug delivery applications where the biodegradation is a
kinetic factor that antecedes the release of the drug into the local environment.
Just as in the case of collagen/CAP composites where the intimacy of the contact between
the two phases determines the stability and other properties of the resulting material, the same
applies to polymer/ceramic composites in general. Unselectively interspersing CAP particles
throughout the polymeric matrix thus presents a less convenient solution than utilizing a more
time-consuming approach whereby hydrolysis of the polymer, e.g. PLLA, is allowed to provide
nucleation sites for CAP crystallites. Interestingly, irregularly shaped particles are favored
because of allowing for the tighter interlocking of polymeric coils around them 98, which explains
why apatite particles in bone are plate-shaped, not spherical, and typified by ruffled
topographies, too. Preventing agglomeration, though, a pervasive problem for most
nanoparticulate formulations, driven by unfavorably high surface energies, is an ever present
challenge and various surface treatments of CAP were proposed as a solution, notwithstanding
the extent to which they would interfere with the impregnation process. These dispersion
problems are particularly challenging when the aim is to uniformly intersperse hydrophilic
nanoparticles within hydrophobic polymers, a task that routinely requires the usage of surface
active agents or chemical functionalization of the polymer with reactive moieties. The
combination of solvents and non-solvents of appropriate polarity can transcend these obstacles
and provide conditions for simple precipitation of composite structures with a fine level of phase
dispersion and homogeneity. Fig.6 correspondingly displays compact and nonporous composite
nanoparticles of PLGA and HAp obtained by a sequential precipitation of the two components in
a method that is both ecologically and geopolitically sound - the former because of its reliance on
eco-friendly chemicals and the latter owing to its inexpensiveness, technological simplicity and
the corresponding facileness with which it could be transferred from the developed to the
developing world stage settings. Another advantage of this composite comes from its
comparatively high drug loading capacity, with both components being able to capture
significant amounts thereof – HAp via surface adsorption and PLGA via bulk entrapment.
Although the fact that HAp has been used in purification systems and in chromatography for the
separation of proteins 99, nucleic acids 100 and microorganisms 101 is already a good indicator of its
excellent drug adsorption capacities, perhaps the best illustration of its binding potential comes
from Ca2+ ions sandwiched as atomic bridges between two phosphate groups, one from a DNA
molecule and another one from zwitterionic dipalmitoyl-phosphatidylcholine, in DNAimmobilized thin films self-assembled using the simple Langmuir-Blodgett technique 102.
Multiple polymers other than the polymers of lactic and glycolic acids are commonly used in
combination with CAP or with other hard components in composites for hard-tissue engineering
applications. These include non-biodegradable polymers such as polysiloxanes 103, poly(methyl
methacrylate) 104 and other acrylics 105, polyethylene 106 and polypropylene 107 among olefins and
poly(vinyl alcohol) 108 among haloalkanes. Biodegradable polymers used in combination with

CAP include hyaluronic acid 109,110 and chitosan 111 as the commonest biological choices, poly(εcaprolactone) 112,113 as another popular polyester, various polyanhydrides and some of the more
rarely used polymers, counting poly-p-dioxanone 114, poly(trimethylene carbonate)115,
poly(ethylene oxide terephthalate)-poly(butylene terephthalate) block copolymer 116, and many
others.

Fig.6. FE-SEM (a-c) and HR-TEM (d-f) micrographs of particles comprising HAp nanoparticles interspersed within
bigger PLGA spheres. Reprinted with permission from Ref.117.

4. Other composite materials
Hard tissue engineering composites have been created using hard components other than
CAPs. As furtherance of the oldest and the most common generation of composites used in
reparative dentistry, composites reinforced by silica particles 118 or bioactive glass 119 present a
particularly popular class of such materials. Various forms of bioactive glass have been shown as
promising candidates for bone replacement composites; for example, foaming of gelatin and an
amorphous mixture of SiO2 and CaO resulted in three-dimensional structures with the pore size
in the 100 – 200 μm range, convenient for the internal culturing of stem cells 120. Bioactive glass
with the SiO2:CaO molar ratio of 5 also slightly improved the compressive strength of PLGA
scaffolds and the osteogenic response of MSCs seeded on them 121. Compared to CAP
nanoparticles typified by swift reorganization of the surface layers and the virtual impossibility
of their chemical functionalization, silanol groups on the surface of silica nanoparticles offer a
far greater stability and more facile functionalization with organic molecules 122. Silicon is also
present in the newly formed bone in the amount of 0.5 wt% 123, and the biological response to
implantation of Si-doped HAp was more positive than for pure HAp 124,125.
Nanotubes present another class of materials considered for application in composites for
hard tissue engineering. For example, carbon nanotube dispersion in a fumarate-based polymer
yielded a material with excellent mechanical performance 126; however, the fate of such
nanotubes in the body is uncertain, as it is difficult to predict based on the implant location
whether they would degrade, migrate elsewhere or be inert. Tungsten disulfide 127 and titania128
nanotubes have also been investigated for a potential application in polymeric composites for
bone replacement. Titania nanotubes have attracted a particular attention because of the

comparative ease with which they could be created as a coating on the titanium implant surface
via electrochemical anodization129. This process is both (a) an alternative to regular etching
procedures that are supposed to increase the intimacy of the tissue/implant interface and that
precede a typical surgical implantation and (b) a mechanism to enable the implant to be loaded
with sustainably releasing drugs. In support of this approach, a significantly lower
thrombogenicity was detected on titania nanotube arrays, as compared to biomedical-grade
titanium, after contact with blood plasma 130. Titania nanotubes have also been shown to be
capable of releasing proteins or antibiotics for hours when immersed in the physiological
solution 131,132. The main problem associated with drug delivery using titania nanotubes comes
from their practical limitation to the first-order release kinetics, typified by the burst release of
the drug in the first couple of hours. Despite the claims that nanotube diameters comparable to
the size of the drug molecules would result in zero-order release kinetics 133, no such release
profiles have been reported to date. Coating the titania nanotube arrays with natural or synthetic
polymers that would somewhat mitigate the burst release was proposed as a solution to this
problem 134. As for composites comprising titania nanotubes, another interesting approach is that
based on arrays of titania nanotubes loaded with both regular and reverse polymeric micelles 135.
They were proven as capable of simultaneously delivering hydrophobic drugs, such as
indomethacin and itraconazole, and hydrophilic ones, such as gentamicin, over a period of 10
days, with the drug release profiles for each drug being highly dependent on the polymeric
micelle ratio.
A special family of composite materials is that comprising titanium as the main
component. Although evidenced for their biocompatibility, superior elastic properties over
ceramics and relatively high toughness compared to other commonly used metals, their main
downside comes from their non-biodegradable nature and an extremely low level of bioactivity.
Also, similar to most metals and alloys, titanium is corrosion-resistant, but not wear-resistant too,
and surface scratches and erosion following implantation serve as an evidence for this effect.
Although clinicians maintain that contamination with metals is mainly due to instrumentation
rather than the implanted metal, long-term exposure to wear debris has caused patients to
develop inflammatory reactions 136,137, frequently followed by periprosthetic osteolysis and
implant loosening, eventually requiring arthroplasty revision 138. In spite of its proven
biocompatibility, the wear of titanium implants, especially in highly load-bearing applications,
such as artificial hips, has led to severe inflammation and subsequent bone loss as the result of
the migration of the eroding particles to regions contiguous with bone 139. Moreover, an ideal
biomaterial from the contemporary tissue engineering standpoint is meant to degrade at the
implantation site at the rate that matches the bone ingrowth rate. However, with the exception of
magnesium, currently the only biodegradable metal researched for its use in drug delivery and
other biomedical applications 140,141, the traditional metallic implants, including those made of
iron, cobalt or zirconium, do not satisfy this criterion. On the other side of the spectrum lie
calcium sulfates, carbonates and very soluble orthophosphate phases, which typically degrade
faster than the rate of new bone formation, leaving gaps in the bony structure and causing severe
drainage at the wound site 142. Weak or nonexistent union with the surrounding bone, corrosion,
fatigue and absorption of mechanical stimuli to such a degree that the adjacent biomechanical
structure partially atrophies or becomes completely resorbed, requiring the surgical removal of
the implant, are all documented in the literature. These disadvantages are attempted to be
overcome by coating titanium with CAP 143,144 or with biopolymers 145,146, hoping that the latter
would promote bone-implant bonding and a more intimate tissue/material interface. Metallic and

ceramic phases in contact, however, have a relatively high tendency to separate, which explains
many instances of delamination and spallation of plasma-sprayed CAP coating layers on titanium
surfaces observed even under comparatively mild testing conditions 147, let alone in much harsher
in vivo environment 148.
Multiple other composites have been investigated for their ability to act as bone grafts
and bone-regeneration implants. An aligned fibrous mesh obtained by electrospinning of poly(εcaprolactone) and reinforced by 10 wt% of magnesium silicate nanopowder has, for example,
improved the tensile strength and elastic modulus of the pure polymer and provided a surface for
an enhanced cell response when compared to the unreinforced meshes 149. Interestingly, poly(εcaprolactone) fibers obtained by the same technique and reinforced by hardystonite, a mineral
with the chemical formula Ca2ZnSi2O7, did not only exhibit a better mechanical performance
compared to the same scaffolds reinforced by HAp, but they also enhanced cell proliferation and
infiltration and promoted a more intense mineralization of the matrix by adipose-tissue-derived
stem cells 150. Siloxane-doped vaterite is another ceramic phase that has been used as an
alternative to CAP in cotton-like PLLA-based scaffolds 151. Composites enriched with silver
nanoparticles have also attracted a particular attention owing to the antibacterial properties of
silver and its consideration as a viable alternative to traditional antibiotics, whose efficacy in
eradicating microbial sources of infection has reached an all-time low. Supplementation of
gelatin/HAp scaffolds with silver nanoparticles has thus resulted in composite materials with 80
% of porosity, able to promote the proliferation of osteoblasts while exerting a strong
bactericidal effect against both gram positive and gram negative bacterial strains 152. Unlike silver
ions, which owe their antibacterial efficacy to the ability to interact with thiol groups in bacterial
enzymes, denature them and induce the disintegration of the cell membrane and the lethal
leakage of its cytoplasmic content 153, other, less popular antimicrobial ions, rely on different
mechanisms to eradicate bacteria. Selenium, for instance, inhibits the S. aureus biofilm
formation and also initiates an oxidative cascade by being reduced to elemental form once
metabolized 154, while gallium serves as an irreducible iron analog under physiological
conditions 155,156. Other antibacterial ions include copper, zinc, cerium, strontium, europium,
titanium and cobalt and all of them are easily incorporable into the lattice of HAp as calcium ion
substitutes 157.
One of the central advantages offered by ceramics as components of composites for hard
tissue engineering comes from the possibility to control an array of their properties by
controlling their stoichiometry, foreign ion inclusion and other parameters that define their total
phase composition, be it isotropic, modular or functionally gradient. Lanthanum-strontium
manganites (La1-xSrxMnO3+δ) exemplify this well, with variations in La3+/Sr2+ molar ratio being
an excellent means of modifying the intensity of superexchange interaction 158 and concentration
of holes in the electronic structure, which affect an array of magnetic and charge transport
properties 159, respectively, endowing the material with a broad application potential. Another
example comes from lanthanum-strontium cuprates (La2-xSrxCuO4), where minor amounts of
dopants could be used to control the ratio between antiferromagnetic, superconductive and
metallic phases of the compound 160. Similarly, CAPs are found in one or multiple phases whose
solubility, alongside mechanical and other properties, ranges from very high, as for MCPs, to
sparsely soluble, as for OCP or HAp. This intrinsic versatility of CAPs and most ceramics in
general allows for tailoring of their properties to match those of hard or soft tissues that they are
meant to replace or regenerate.
On the other hand, one of the basic premises of materials science is that the structure of a

material is an equally essential determinant of its properties and the performance as its chemical
composition is. For example, a chemically identical metallic material can act as a conductor, a
semiconductor or an isolator depending on the concentration of grain boundaries and similarly
broad effects of the microstructure have been observed with respect to the biological response to
materials. Whether a compound is predisposed to exert a toxic, a neutral or a healing effect on
the body is, thus, oftentimes determined by its structural parameters, such as the grain size 161,
crystallinity 162, the dominant polymorph 163, porosity 164, and the morphology of pores 165 and
particles 166. This principle becomes even more accentuated for composite materials wherein the
number of possible interactions between the components is multifold. Just like randomly
combining HAp and collagen is no guarantee that a composite structure as stable and sturdy as
bone will be produced, so does it frequently occur that two composites formed from identical
components, but by slightly different means, yield drastically different end results. Such was the
case with chitosan-HAp scaffolds whereby the air-dried ones demonstrated a threefold increase
in compressive strength over the freeze-dried ones 167, suggesting that even at the final processing
stages changes can occur that dramatically affect the interaction of the components at the nano
and molecular scales. After all, if sheer solvent desorption and resorption was enough to cause
reversible structural transformations in 3-nm-sized zinc sulfide particles 168, the structure of softer
nanoparticles must be even more amenable to such post-processing effects. Naturally, also, with
an increase in the number of the components, the assortment of the possible symmetries of their
ordering increases too. An additional advantage offered by composite materials is the possibility
of creating different symmetries at different scales, from the molecular to the micro scale, an
effect that is achieved much more facilely than by single-phase materials.
5. Additional common ingredients of composite biomaterials
Unlike cartilage, which is home to a single cell type, multiple types of cells populate
bone, including, most importantly, osteoblasts, osteoclasts and osteocytes. Osteoblasts are cells
that do not only secrete proteins that constitute the bone matrix and induce calcium deposition
within the fibrillar collagen network, thus promoting mineralization of bone, but also have
immune functions, as they express cytokines to attract leukocytes and phagocytes to the wound
or infection site. Yet, although they complement fibroblasts in making hard tissues (rather than
the soft ones that fibroblasts make), both genotypically and morphologically they are hardly
distinguishable from them. Namely, all the genes expressed in fibroblasts are expressed in
osteoblasts too, while only two osteoblast-specific RNA transcripts have been identified so far:
one encoding for Runx2, a.k.a. Cbfa1, a transcription factor and a key regulator of osteoblast
differentiation, and the other one encoding for osteocalcin, the most abundant non-collagenous
protein of the bone matrix, which serves as a nucleation center for the mineral particles and
which, conversely, inhibits osteoblast function and attracts the antagonistic cells known as
osteoclasts 169. A considerable difference in stiffness between the two cell types exists though:
while the elastic modulus of fibroblasts is ~ 3 kPa, that of osteoblasts is ~ 20 kPa 170. Osteoclasts
secrete lactic acid and proteolytic enzymes that dissolve the mineral and digest the organic
matrix of bone. These multinuclear cells derived from hematopoietic stem cells (HSCs) and
related to macrophages also phagocytize mineral particles in addition to dissolving them via acid
secretion. In coordination with each other, these two mutually antagonistic types of cells,
osteoblasts and osteoclasts, contribute to constant remodeling of bone in response to various
biochemical and mechanical stimuli, an effect that is perhaps best demonstrated by the

significant bone loss and osteopenia experienced by bedridden patients and astronauts who spend
prolonged periods of time in microgravity conditions 171. Surrounded by osteoid, the organic
matrix of bone, osteoblasts stop creating the bone matrix and become quiescent osteocytes, cells
involved in signal transduction of mechanical stimuli, the task that they achieve by secreting
hormones, e.g. sclerostin, which inhibits bone formation in response to mechanical stress 172.
Osteocytes are essentially progenitory cells, which, in contrast to multipotent and indefinitely
replicable stem cells, are oligopotent at best and can replicate only a limited number of times.
Bone marrow does contain MSCs, although to a very minor extent: only 0.001% of the cellular
content of bone marrow, with their proportion decreasing with age. Still, isolated MSCs could
undergo over 30 passages, or more than a billion-fold expansion, without losing their osteogenic
potential 173. In addition to these pluripotent cells, bone marrow is also a reservoir for HSCs that
differentiate into erythrocytes and leukocytes, cells involved in the transport of nutrients and
immune resistance, respectively174. Correspondingly, viable interaction with cells evaluable in
vitro presents the first step in estimating the clinical suitability of a biomaterial and Fig.7 shows
an example in favor of composite nanoparticles. Namely, when vitamin D3 is delivered directly
off the surface of HAp nanoparticles, on which it was physisorbed, the effect on the osteoblastic
cell is nowhere as viable as that when the delivery is mediated by a surface layer of polymer, in
this case PLGA 175.
Therefore, the first and the foremost additional component of materials for bone tissue
engineering applications includes cells, on whose type, density, cell cycle stage and other
genotypic and phenotypic characteristics the biological performance of the composite will come
to depend. Most often, cells sucked into the scaffold are autologously derived so as to avoid the
immunological response. When cells are delivered together with an implant, sufficient porosity
and pore connectivity must be embedded in the material, lest the cells in its interior undergo
necrosis due to the hindered transport of nutrients and waste products. No cell in the body is
farther than a couple of hundreds of microns from a blood vessel and the same principle is to be
applied in the design of biomaterial scaffolds. Note that microporous materials are defined as
those with the pore diameters of less than 2 nm; macroporous materials have the pore diameters
larger than 50 nm, while the mesoporous category lies in the middle 176. However, the size of the
pores in scaffolds has to be much larger, beyond the “macroporous”, in the order of tens or
hundreds of microns, for the cells to be accommodated therein. Moreover, creating a surface-tobulk gradient of the pore size may prove to be favorable, as suggested by the study that
demonstrated the most successful implants in regenerating osteochondral defects in rabbits to be
PLGA scaffolds with 100-200 µm pores in the chondral layer and 300-450 µm pores in the
osseous layer 177. Scaffolds, ideally, should not only possess a multimodal distribution of pores,
but the right connections between pores could be considered to be of an even greater importance.
The intercellular fluid and cells need to flow and communicate through signaling, respectively,
and there are ongoing research efforts aimed at finding the most optimal networks of pores for
the proliferation of cells within. Until now, electrospinning has been by far the most common
method used to make porous polymeric scaffolds, with particulate leaching and thermallyinduced phase separation being the other two most frequent synthesis routes 178.

Fig.7. Z-stacked confocal optical micrographs of osteoblastic MC3T3-E1 cells incubated with no nanoparticles (a),
with HAp nanoparticles loaded with vitamin D3 (b), and with HAp nanoparticles loaded with vitamin D3 and coated
with PLGA (c), fluorescently stained for the cell nucleus (blue) and cytoskeletal f-actin (red) following 4 days of
incubation. The size of each image is 300 x 300 μm.

The second type of commonly used ingredients belongs to growth factors and particularly
bone morphogenetic proteins (BMPs), which promote osteogenic differentiation of the cells and
the building of new bony tissues 179,180,181. The central problems associated with their application
spring from (a) their sensitivity and proneness to environmental degradation, (b) necessity of
accomplishing precisely tuned and optimized delivery profiles, and (c) expensiveness of
production through recombinant techniques, all of which limits the scope of their practical
applicability. The burst release of growth factors is, additionally, considered unfavorable from
the point of view of optimal bone regeneration, as their controlled and prolonged release is of
vital importance to make the material osteoinductive 182,183. Also, tumorigenesis, ectopic
expression and other forms of ill-directed growth resulting from the uncontrolled dosage or
location of delivered BMPs and other growth factors, including platelet-derived growth factorBB, and present serious potential problems pertaining to their usage 184,185,186,187. Strictly
speaking, with the healing process following injury that the implantation of a hard tissue
substitute is consisting of multiple steps, including clotting, angiogenesis, inflammation, scar
formation, etc., each one of which occurs at a narrowly defined time scale, it makes sense that
regulatory molecules targeting these specific events should be released within similarly narrowly
defined time windows. For example, blood clotting occurs in the first few hours following
surgery and any sustained delivery of a molecule affecting this biological process over a period
of days or weeks would not make much sense. Similarly, the immediate, burst release of a drug
targeting inflammation, which takes over the biomaterial/tissue interface gradually, usually
intensifying itself during the first couple of days after the implantation, would be similarly
illogical from this point of view that necessitates precise tuning of the drug release profiles to the
corresponding physiological events.
Antibiotics and other pharmaceutics present an important class of compounds frequently
delivered using bone implants 188. As for the former, their purpose is either prophylactic, that is,
to prevent a postsurgical infection from developing, or deliberately antimicrobial in the cases
when an infection has already been diagnosed. Composite nanostructures accommodating HAp
in combination with polyesters, such as PLGA, have thus been intensely researched for their
potential use in the delivery of antibiotics to infected bone and the treatment of osteomyelitis 189.
Capable of being loaded with both hydrophilic and hydrophobic drugs, ranging from those
effective in the treatment of infections caused by opportunistic S. aureus and S. epidermis to
anti-tuberculosis drugs, they are also formable as scaffolds with accurately designed porosities
using 3D printing techniques 190. An important advantage of this family of composite materials is

their potentially allowing for tunable multiple-stage release profiles even more complex than the
three-phase kinetic profiles typical for polymeric microparticles. In those cases, the initial burst
release (~ 20 % in the first 4 – 6 h) results from the drug either adsorbed on the surface or
entrapped within the first few surface layers of the degrading particles. The second phase
involves sustained release dependent on the mechanism of degradation of the polymeric matrix.
Polyesters, such as PLLA or PLGA, degrade through bulk erosion whereby the water uptake is
faster than the degradation of the polymer and the drug release occurs without a significant loss
of mass or volume of the polymer 191,192. In contrast, polyanhydrides degrade via surface erosion
whereby the hydrolysis proceeds faster than the water ingress into the interior of the polymeric
particle 193. The third stage is characterized by a slight increase in the release rate and it takes
place as the degradation nears its completion 194. In the case of acidic polyesters or
polyphosphazenes, the release of acidic byproducts is responsible for the autocatalytic
acceleration of the degradation process at this stage. It has been argued that these multiple-stage
release profiles can have great benefits compared to solely linear profiles. For example, it was
shown that the rapid initial release of paclitaxel stopped the proliferation of a tumor, while a
more sustained, second phase of release allowed for its complete gradual eradication 195.
Compounds that stimulate the production of BMPs and thus indirectly enhance bone
formation have been a part of the repertoire of additional ingredients of composites for bone
regeneration and have predominantly included statins 196. Icaritin, an exogenous phytoestrogenic
compound, was combined into a composite PLGA/TCP scaffold and its sustained release
enhanced the bone defect repair in the rabbit model of steroid-associated osteonecrosis 197.
Plasmids are rarely delivered by means of hard tissue replacement materials, though it has been
shown that both CAPs 198,199 and polycationic polymers, e.g. polyethylenimine/hyaluronic
acid 200, can complex DNA and be used as non-viral gene delivery carriers, though still in a less
efficient way than it can be achieved by means of the viral ones. Cytokines and antibodies
present other deliverable biomolecules of interest capable of fostering a favorable cellular
response that promotes new bone formation. Attaching cell-binding peptides to the surface of the
particles or entrapping them in their interiors so as to promote a more favorable cell/material
interaction also presents a potentially valuable approach. Various host-cell specific moieties and
cell-penetrating peptides could be employed as functional surface groups with the aim to
promote a more intimate tissue/material interface. As for the latter, enrichment of composites
with analogues of lipofectamine, a positively charged compound used in gene transfection
protocols to facilitate the diffusion of exogenous oligonucleotides across the cell membrane 201,
can be considered as an option. One of the peptides commonly used to improve the
biocompatibility of the implant is Arg-Gly-Asp (RGD) 202,203. A part of many proteins of the
extracellular matrix, this peptide has been shown to promote cell adhesion 204, proliferation 205 and
differentiation 206 in multiple cell types. Next, despite the fact that wound healing following bone
injury and placement of an implant involves blood clot formation, which has a significant effect
on the outcome of the healing process, “most research in bone tissue engineering virtually
ignores the important role of a blood clot in supporting healing” 207. To that end, it is only a
question of time when the control over this physiological process will be exerted using additional
ingredients of regenerative constructs in hard tissue engineering. Tissue plasminogen activator (tPA), a protein involved in dissolving blood clots, was, for example, conjugated to the cationic
polyurethane surfaces and gold nanoparticles capped with poly(vinyl pyrrolidone) and lysine,
which had a multifold effect on the extension of its half-life 208,209, while another approach
pertains to the fabrication of clot-lysing surfaces as those having selective affinity for

plasminogen and t-PA, which, when combined, yield plasmin able to dissolve the fibrin clot.
Using such agents in combination with their antagonists, the blood coagulation process in the
vicinity of the implant could be optimized, having a positive effect on bone regeneration.
Functionalizing the composite systems with antagonistic pairs of peptides allows for the
use of such composites as smart therapeutic devices, capable of releasing drugs in direct
feedback with the demands of the biological microenvironment. As suggested by a study by Wu
et al. 210, reservoirs holding an antiresorptive drug, aimed to diminish the activity of osteoclasts,
could be linked to (Asp)8 sequence, whereas those storing an anabolic drug, aimed to stimulate
osteoblasts, could be linked to (Asp-Ser-Ser)6 targeting peptide. It is worth noting that
antiresorptive drugs per se, including primarily estrogen receptor agonists and various
bisphosphonates, such as alendronate 211, clondronate 212 and others, have also been successfully
co-delivered together with other therapeutics. Bisphosphonates are also interesting because of
their ability to act as bone-targeting agents, ensuring the localization of the nanoparticles at the
bone interface even when injected into the bloodstream 213. Still, the effects of coupling such
agents to antifouling peptides 214, capable of exhibiting either a prophylactic or a
straightforwardly antibiotic effect by preventing the formation of the biofilm or breaking it
down, respectively, have yet to be explored. Some proteins could be reduced to only a dozen of
amino acid residues long peptides and still maintain the gross of their functionality 215 - such
methods could prove to be practical in the design of peptides capable of inducing the right cell
response. The benefits of the delivery of peptides come from their structural sturdiness compared
to large proteins, which have low cellular permeability and low stability, being sensitive to
mildest deviations from the physiological conditions and/or the action of proteases. Even when
they reach the interior of a cell, they may be detected as foreign entities and degraded as such in
the lysosome. Yet, it is nowadays known that proteins can also cause the cells to change
the identity through the epigenetic route 216, the role that was prior to this discovery thought to
have been reserved for nucleic acids only. This also explains why a large body of research is
being dedicated to vesicular capsules and other protein carriers 217. Note that the time scale for
the adsorption or chemisorption of peptides onto inorganic particles is different depending on the
complexity and the level of symmetry of the interacting protein assemblies. Side chains typically
bind on the scale of nanoseconds, individual protein molecules on the scale of seconds, clusters
of peptides require minutes, and layers of peptides may need hours. The choice between the bulk
entrapment, nonselective physisorption and covalent binding depends on the type of molecule in
question. In the case of nonspecific adsorption, electrostatic attraction, van der Waals forces and
entropic driving forces, as in the hydrophobic effect, are relied on to achieve stable binding.
Typical chemical conjugation mechanisms involve reactions between amines and activated
carboxylic acid groups as esters with a good leaving group (e.g., using alginic acid to form
carboxyl surface groups and then n-hydroxysuccinimide or trifluoroacetic anhydride to
deprotonate them into reactive carboxylate groups) yielding amide bonds, between
pyridyldithiols and thiols yielding disulfide bonds, between acetyls and azides yielding triazole
bonds, between maleimide derivatives and thiols yielding thioether bonds, between amines and
thiocyanates yielding isothiourea bonds, between surface p-nitrophenylcarbonyl terminal groups
and amine ligands yielding carbamate bonds, and so forth 218. Noted in the literature are also a
variety of azide-alkyne cycloadditions, a.k.a. “click” chemical reactions used to bind drugs or
targeting moieties to a plethora of polymeric micelles and nanoparticles, liposomes, metallic and
silica nanoparticles and carbon nanotubes 219,220. Note also that different materials require
different methods to achieve stable surface functionalization: co-precipitation or ion exchange

may be sufficient for CAPs, chemisorption is most optimal for polymers, while functionalization
of carbon-based materials, including nanotubes and graphene, requires derivatization via
carboxylic moieties introduced by a combined acid and permanganate ion oxidation treatment221
and is greatly facilitated if structural defects are created in the first place 222.
Functionalization with poly(ethylene glycol) (PEG) presents another routine approach in
the drug delivery field. The rationale is that passivation with hydrophilic PEG produces random
coiling at the surface, which entraps water and prevents opsinization and rapid clearance by the
reticuloendothelial system. As a result, conjugation with PEG is able to: (a) sterically stabilize
particles and prevent the binding of plasma protein, thereby prolonging the pharmacokinetic
half-life in circulation and increasing the bioavailability of the drug; (b) reduce immunogenicity;
and (c) enhance permeability and retention effect 223. Labeling the particles with technetium-99,
indium-111 or iodine-125 224 for radiological bone scintigraphy, doping them with luminescent
ions for imaging purposes or with magnetic ions, ranging from iron to gadolinium to cobalt 225,
for use in MRI applications, in hyperthermia treatments and for magnetic-field-assisted bone
growth enhancement are other interesting, though largely unexplored research avenues, even
though they could present steps forward in the direction of smart, theranostic biomaterials for
bone regeneration, capable of acting therapeutically in direct feedback with the outcome of in
situ disease monitoring at the cellular and subcellular scales. Which brings us over to the central
advantage offered by the future generation of composite therapeutic systems: smart, synergistic
and multifunctional response to demands of the local microenvironment.
Interestingly, the recently made composite particles comprising silver nanoparticles
coated with PGA and embedded together with ascorbic acid in submicron PLGA spheres,
possessing a triple functionality – antibacterial, osteoinductive and antioxidative – upregulated
the expression of osteocalcin and type I procollagen without the release of any growth factors 226.
Transcending the need for the delivery of chemical agents as sources of bone growth marker
upregulation by the right structural synergy between the composite components is bound to
present an ever more exciting topic of research in this field. Advancements along this line of
research have the potential to finally erase the traditional division of biomaterials for bone
engineering applications to three categories: osteogenic, osteoinductive, and osteoconductive. As
a reminder, osteoconduction is a process whereby an implant facilitates the ingrowth of blood
vessels and the migration of bone cells capable of osteogenesis onto it. Therefore, a material that
supports bone growth on itself by definition demonstrates osteoconductivity. Osteoinduction, in
turn, implies the recruitment of pluripotent MSCs from the surrounding tissue and induction of
their differentiation into osteoblasts, a process that is mediated by the growth factors, specifically
bone morphogenic proteins. Accordingly, osteoinduction is thought to be achievable only with
the delivery of osteoinductive factors, which include bioactive chemicals capable of inducing
recruitment, differentiation and proliferation of bone cells. CAPs per se are, according to this
definition, only osteoconductive and only an addition of growth factors is supposed to be able to
render them osteoinductive. Yet, their ability to upregulate the expression of osteogenic markers
and boost the osteoblastic differentiation, making them effectively osteoinductive too, has been
reported on numerous occasions 227,228,229. The addition of growth factors, such as bone
morphogenetic proteins, has indeed made CAPs osteoinductive 230,231, although the same
osteoinductive effect achieved by BMP-2 on human MSCs was accomplished by nanosized HAp
particles, for example 232. Surface features and precisely set morphologies are also capable of
compensating for the effects of sole chemistry and acting as critical osteoinductive agents. Not
only do the size and the geometry of the surface features and the distances between them matter

in this sense, but the order/disorder at the level of their translational symmetry matters too, as
shown in Fig.8. Namely, the gene expression of osteocalcin, osteopontin, procollagen type I,
alkaline phosphatase, and the transcription factors Runx2 and TGFβ-1 was consistently
upregulated only in osteoblastic cells seeded on translationally ordered composite films made by
dispersing HAp nanoparticles in a 80 kDa poly(ε-caprolactone) matrix, as opposed to
translationally disordered and flat surfaces of the same composition 233. Many prior studies have
shown that topography can be a more important determinant of the viability of the
biomaterial/tissue interface than the surface chemistry or stiffness 234,235,236. This finding has,
however, implied that the order at the level of the distribution of topographic features can be a
more decisive factor than their surface density, size and geometry. This is all to say that the
research possibilities in the design of advanced nanocomposites for bone tissue engineering
really seem limitless, concealing unforeseen clinical potentials, the unleashing of which the
devotees to this exciting field of materials science, as of today, unreservedly anticipate.

Fig.8. Upregulated mRNA expression of osteocalcin (BGLAP), osteopontin (BSP-1), procollagen type I (Col I),
alkaline phosphatase (ALP), and the transcription factors Runx2 and TGFβ-1 in osteoblastic MC3T3-E1 cells grown
on (a) topographically ordered nanocomposite poly(ε-caprolactone)/HAp films compared to the same cells grown on
the control cell culture polystyrene (gray bars) and on (b) topographically disordered and (c) flat poly(εcaprolactone)/HAp films. The photolithographically fabricated cylindrical surface features have 10 μm in diameter
and 10 μm in height and are spaced by 10 μm (edge-to-edge) on average in both films (b) and (c). mRNA expression
was measured by quantitative RT-polymerase chain reaction relative to the housekeeping gene β-actin (ACTB). Data
first normalized to the expression of ACTB and then to the gene expression of the control group are shown as
averages with error bars representing standard deviation. Genes significantly (p < 0.05) upregulated with respect to
the control group are marked with *. Genes significantly (p < 0.05) downregulated with respect to the control group
are marked with †.

6. Outlook

The demand for a new generation of bone replacement materials has never been higher,
given more than 2 million bone graft operations performed annually worldwide 237 (600,000+ in
the US alone) 238 and the constant increase in this number owing to the aging population of the
Earth. The medical costs of bone graft placement have reached $1.3 billion in 2010 and continue
to rise at the 7.4 % annual rate 239. Bone graft business has simultaneously thrived in the recent
years, generating revenues in the excess of $2.5 billion per annum 240. As of today, however, only
about twenty tissue engineering applications, mainly for skin and muscoskeletal regeneration,
have been approved by the FDA and made available on the market. The current generation of
bone substitutes suffers from numerous demerits, including insufficient strength for load-bearing
applications, widely varied resorption times, insensitivity with respect to the application zone in
the bone and in the body, insufficient drug release tunability, and the lack of control over the fate
of internalized and adhered cells and biomolecules. Despite the fact that there is not too many
sites in the body from which bone could be harvested without causing a biomechanical
dysfunction or unaesthetic disfigurement, allografts and autografts as parts of hard tissues taken
from donors or the patient itself, respectively, still constitute the greatest majority of materials
used as bone grafts in the orthopedic surgery, with only 5 % or less being synthetic materials.
While the downside of autografts is the necessity for two separate surgical procedures to be
performed, increasing the risk of infection and failure, allografts pose a risk of implant rejection
and disease transmission, including the need for an extensive sterilization procedure during
which the properties of the filler are often degraded. If we add the relative inflexibility of
autografts in filling irregular defects and their propensity to be resorbed too rapidly, we could
come to conclusion that there is a serious discrepancy between the bone substitutes routinely
applied in the clinic today and the quality and potentials of those lying scattered across the
‘valley of dreams’ of the research stage and the so-called ‘valley of death’ of the translational,
preclinical stages.
Materials for hard tissue engineering applications in the research phase, on the other
hand, greatly outnumber the limited number of those that are currently available to the clinicians.
And with no material able to replicate bone anywhere in sight, we could be certain that the
research race will continue towards the destination that is a perfect biomaterial for the
regeneration of hard tissues. Considering a variety of hard tissues within the organism, we could
be equally certain that more than one such perfect biomaterial awaits us at this ultimate aim of
our research ventures. Understanding this is equally enlightening as the realization that not a
single worldview could be enough to reflect the phenomenal complexity of life. Rather, only a
combination of mutually differing points of view can account for a view of life that is truly
complete. Of course, endorsing composite replacements of naturally composite boney tissues
comes at the cost of a pervasive concern that an undesirable synergy among the multiple particle
components might be produced, the reason for which natural medicines have been traditionally
disfavored over monomolecular synthetics. Such synergies resemble double-edged swords in a
sense that they could be positive, as in the case when the delivery of clindamycin with CAP
nanoparticles canceled out the negative effect that the administration of the pure antibiotic had
on the osteogenesis of the bone tissue 241 or in the case when the co-delivery of rapamycin and
paclitaxel using nanoparticulate poly(ethylene glycol)-poly(ε-caprolactone) block copolymers
had a greater antitumor efficacy than the delivery of the two drugs alone 242, but they could also
be detrimental, as in the cases when increases in toxicity entailed combination drug
therapies 243,244 or when binding of fluorophores caused the unintended deformation of the
labeled biomolecules 245, including even the crystal lattice of CAPs 246. Whatever the case,

synergies are inescapable in composite systems and their protean effects, rising steeply in
proportion with the number of interactive components, must be carefully assessed prior to the
medical application of their therapeutic carriers.
Great disparity exists between the current generation of composite materials clinically
applied in the restoration of hard tissues and the far more sophisticated types of composites
elaborated in this discourse. This gap becomes clearly obvious when we put side by side the
rather rudimentary composites used today by dentists, maxillofacial surgeons and orthopedists
and the fantastic, ultra-finely structured and multifunctional composites towards which the future
of the materials science is streaming. For example, titanium implants coated with the bioactive
layer of HAp have a favorable effect on bone integration, but they do not overcome the problem
of elastic modulus mismatch between the implant and the bone and the corresponding stressshielding effect, which tends to lead to bone resorption, the loss of tissue/implant union and an
increased likelihood of fracture. Also, the rather weakly bound, thin and porous bioactive HAp
layer is only temporarily existent in vivo and after only a few weeks or months at best all but the
ideal titanium/tissue interface is restored and with it all the imperfections tied to it. Its long-term
benefits are questionable because, although it does speed up the host response, the tissue
interface eventually looks the same, with or without it. Another type of clinically applied
nanocomposites, based on the combination of PLGA and nanostructured HAp, suffers from the
insufficient strength as the result of the low mechanical synergy between the hard and the soft
components as well as from the risks of bone resorption and inflammation associated with the
burst release of acidic products of the autocatalytic degradation of the polymer.
Demerits of the current generation of nanocomposites used in bone replacement
procedures are actually too many to fit the content of this review. For example, biodegradable
load-bearing bone replacement materials are neither available on the market nor existent on the
horizon. Then, practically all of these options are isotropic, which contrasts the fact that the
mechanical properties of compact human bones are anisotropic and depend on the direction of
the applied force, being stronger in both tension and compression modes when the load is applied
parallel to the direction of its long axis than when it is applied normal to it. Also, even though
they are drastically different in porosity, strength, vascularity, turnover rate and mechanical
properties 247, the cortical and the trabecular bone are usually treated with identical fillers. This is
all to say that every single composite used in bone restoration today suffers from obvious
deficiencies. In contrast, as we could have seen from the present discourse, the composites
currently in the research stage outweigh in their complexity and the potential those in use today.
Once we see the former fully transitioned to the bedside, it will certainly be a great triumph for
this loose confederation of materials scientists and medical professionals that we have today.
The most revolutionary breakthroughs in the development of nanocomposites for bone
regeneration will certainly belong to smart, multicomponent systems capable of delivering
therapeutic payloads at the ideal location by means of the right targeting agents and at the ideal
time points through release triggered by an in situ detection of disease markers. This perfectly
accurate spatial and temporal delivery of therapeutics is in need of theranostic systems guidable
by inbuilt molecular recognition codes to the right location in the body as well as programmed to
release the therapeutic cargos in an environmentally sensitive way, in direct feedback with the
outcomes of in situ disease monitoring via an embedded diagnostic module. Nacre-mimicking,
multilayered particles with preset layer degradation rates, functionally gradient particles with
structure and properties scaled to provide an ideal biological response, and Janus particles with
either/or logic of release present some of the exciting nanocomposite forms that will overcrowd

the literature in the coming decades. Beaver’s enamel owing its exceptional hardness and
resistance to acid attack to the atomically thin, graded layers of ferrihydrite and amorphous ironrich CAP enveloping the apatite nanorods 248 or Pt3Ni alloys displaying enhanced catalytic
properties compared to pure Pt owing to the Ni-free first atomic surface layer 249 could be
instructive examples in terms of fostering the atomically precise surface design of composite
structures. Because nanoparticles may display a wide spectrum of properties in a narrow window
of sizes 250 and abruptly transition between states under marginal changes in size 251, tuning
nanoparticulate ingredients of biocomposites to precisely optimized sizes (alongside other
physical features - shape, topology, microporosity, surface potential, etc.) so as to harness their
unique properties is an approach that will lead to exciting biomaterials in the times ahead of us.
We know now that cell-cell communication is essential to prevent the development of
malignancies, yet we are nowhere near the design of intelligent nanoparticles that share
information with one another, which is yet another breakthrough that we are bound to witness in
the foreseeable future. Seeing particles as predominantly relational entities may also entail the
substitution of the frequently militaristic metaphors describing their therapeutic role in the body
with organic ones, more conducive to the healing process 252. All hard tissues are also
hierarchical structures, possessing distinct symmetries at different spatial scales, and their
artificial replicas may need to be similar in superstructure to serve as their ideal substitutes - i.e.,
isotropic and with unique orderings of nanoparticulate units and their assemblies at the
molecular, nano, micro and macro levels. It is important to note that synergy between the
individual components in these forthcoming composite materials will stem from their
entwinement at ultrafine scales. Of course, the clinical prospect of such sophisticated structures which may eventually really earn the right to be called devices - will critically depend on the
ability to design and create them by elegantly simple and cost-effective means.
Finally, note that most of the composite materials elaborated in this review piece were
biodegradable in nature. Such a choice is in line with the contemporary belief that an ideal
biomaterial is to become fully replaced by the healthy tissue(s) and, ideally, convert the
regenerated area of the body to its original, fully functional state. Regenerative approach to tissue
engineering has been, in fact, the paradigm of our times. It, itself, is an inverted version of the
paradigm that surrounded the birth of the field of biomaterials in the form that we know it today,
that is, around the time the term “biomaterials” was coined at Clemson University symposia in
the 1960s. Namely, although materials science aficionados amongst surgeons are credited for
devising the first biomaterials in the real sense of the word, the first research in “biomaterials”
was done by traditional materials science expatriates, who brought along with them the central
materials science paradigm and instated it on this new territory: “Materials should be made as
stable, sturdy and durable as possible”. As a result, for better or worse, metals became the first
biomaterials for the replacement of hard tissues and improving their resistance to corrosion and
wear (i.e., structural stability in biological environments) the object of the first research in this
field. Right after them on the list of interest were initially non-biodegradable polymers, such as
poly(methyl methacrylate), polyethylene and poly(vinyl chloride). Degradation of biomaterials
went on to be viewed as an unfavorable process by causing the properties and the performance of
the materials to deteriorate with time. It took a whole new look at things, stemming,
interestingly, from a wish not to correct a problem, but to use it as a solution for a problem
existing in a different domain, before biodegradable materials gained value in the biomedical
community. While not disputing the definite merits, alongside an intrinsic beauty, of this new
paradigm, this author, however, believes that an interest for a new generation of materials will be

discovered in the near future. These materials would be fundamentally different from their
biodegradable predecessors and intended to be superior in performance in comparison with the
substituted tissues, be they fully functional or defective.
This viewpoint echoes the dreams of Daedalus, who created wings for his son so as to
make him fly, or, in other words, go beyond nature. Fulfillment of these Daedalus’ dreams would
give a whole new meaning to the equation placed in the title of this work: 1 + 1 > 2. Namely, this
next generation of biomaterials envisaged hereby would be designed with the purpose of not
restoring the tissues, but rather augmenting them. As an intended result, the combination of a
biomaterial and the body would yield something more and beyond the body in question, let alone
a simple sum of the two. Biology has inspired the design of numerous advanced materials in
practical use, but ever since steel and titanium alloys were introduced to bone engineering from
aerospace industry, no advanced materials made it through the translational path from the
materials science lab into the orthopedic clinic despite their great promises, with quantum dots,
carbon nanotubes and fullerenes being some of the notable examples. Even worse, from the
ideological standpoint, biomaterials science has distanced itself from Daedalus’ dream and
embraced a more down-to-earth and organic perspective, attempting to restore the biology at
birth instead of boldly go beyond it in structure and functionality. Needless to add, this is in
direct disparity with the point of view held by molecular biology, where genotypic and
phenotypic manipulations for the purpose of eliciting responses vaguely dormant in cells are
regularly targeted. In view of this, one thing is certain: ‘tis the idea whose time has yet to come
and, like many wonderful ideas, this one, too, takes us to the moment of the conception of the
field discoursed on, drawing a full circle between the beginnings and ends. The exigency of its
elaboration cannot be overstated, yet in spite of the author’s belief in its critical importance for
the future of the field, it will present the topic of some future treatises.
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